New roles for mononuclear phagocytes in cancer biology

Journal of Pediatric Hematology/Oncology

Volumn 30, Issue 8, 2008, Pages 584-591

  Jubinsky, Paul T ^a   Dickens, David S ^b   Short, Mary K ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Helen DeVos Children's Hospitalz   (United States)

Author keywords

Angiogenesis; Dendritic cells; Hypoxia; Immune surveillance; Invasion; Macrophage; Metastasis; Tumor progression

Indexed keywords

COLONY STIMULATING FACTOR 1; INTERLEUKIN 8; MATRILYSIN; MEMBRANE ANTIGEN; PHOSPHATIDYLSERINE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BURKITT LYMPHOMA; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CANCER PATIENT; CARCINOGENESIS; CELL GROWTH; CELL LINEAGE; CELL SURVIVAL; CELL THERAPY; CHILDHOOD CANCER; CLINICAL PROTOCOL; DENDRITIC CELL; ENDOMETRIUM CANCER; ENDOTHELIUM CELL; HUMAN; IMMUNE RESPONSE; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MACROPHAGE; MELANOMA; METASTASIS; MONOCYTE; MONONUCLEAR PHAGOCYTE; NEUROBLASTOMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; UTERINE CERVIX CANCER; CELL DIFFERENTIATION; CYTOLOGY; FEMALE; IMMUNOLOGY; NEOPLASM; PHAGOCYTE; PHYSIOLOGY; RETICULOENDOTHELIAL SYSTEM;

CELL DIFFERENTIATION; FEMALE; HUMANS; MONONUCLEAR PHAGOCYTE SYSTEM; NEOPLASMS; PHAGOCYTES;

EID: 53749088509     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31816e2358     Document Type: Review

References (137)

1. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159-2169.
2. Leek RD, Landers RJ, Harris AL, et al. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer. 1999;79:991-995.
3. Schoppmann SF, Fenzl A, Nagy K, et al. VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery. 2006; 139:839-846.
4. Ohno S, Ohno Y, Suzuki N, et al. Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res. 2004;24: 3335-3342.
5. Salvesen HB, Akslen LA. Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int J Cancer. 1999;84:538-543.
6. Hanada T, Nakagawa M, Emoto A, et al. Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol. 2000;7:263-269.
7. Lissbrant IF, Stattin P, Wikstrom P, et al. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol. 2000;17:445-451.
8. Chen JJ, Lin YC, Yao PL, et al. Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol.2005;23:953-964.
9. Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 2005;106:2169-2174.
10. Nelson D, Ganss R. Tumor growth or regression: powered by inflammation. J Leukoc Biol. 2006;80:685-690.
11. Koide N, Nishio A, Sato T, et al. Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus. Am J Gastroenterol.2004;99:1667-1674.
12. Fan J, Chen Y, Chan HM, et al. Removing intensity effects and identifying significant genes for Affymetrix arrays in macrophage migration inhibitory factor-suppressed neuroblastoma cells. Proc Natl Acad Sci USA. 2005;102:17751-17756.
13. Wilson JM, Coletta PL, Cuthbert RJ, et al. Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology.2005;129:1485-1503.
14. Egami K, Murohara T, Shimada T, et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest.2003;112:67-75.
15. Leek RD, Harris AL. Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia. 2002;7:177-189.
16. Grimshaw MJ, Balkwill FR. Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation-a potential mechanism. Eur J Immunol. 2001;31:480-489.
17. Leek RD, Lewis CE, Whitehouse R, et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996;56:4625-4629.
18. Harmey JH, Dimitriadis E, Kay E, et al. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann Surg Oncol. 1998;5:271-278.
19. Xiong M, Elson G, Legarda D, et al. Production of vascular endothelial growth factor by murine macrophages: regulation by hypoxia, lactate, and the inducible nitric oxide synthase pathway. Am J Pathol. 1998;153:587-598.
20. Lewis JS, Landers RJ, Underwood JC, et al. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol. 2000;192: 150-158.
21. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66:605-612.
22. Cobleigh MA, Tabesh B, Bitterman P, et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res. 2005;11:8623-8631.
23. Vicioso L, Gonzalez FJ, Alvarez M, et al. Elevated serum levels of vascular endothelial growth factor are associated with tumorassociated macrophages in primary breast cancer. Am J Clin Pathol. 2006;125:111-118.
24. Peng SH, Deng H, Yang JF, et al. Significance and relationship between infiltrating inflammatory cell and tumor angiogenesis in hepatocellular carcinoma tissues. World J Gastroenterol. 2005;11: 6521-6524.
25. Chapple KS, Scott N, Guillou PJ, et al. Interstitial cell cyclooxygenase-2 expression is associated with increased angiogenesis in human sporadic colorectal adenomas. J Pathol. 2002;198: 435-441.
26. Kataki A, Scheid P, Piet M, et al. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med. 2002;140:320-328.
27. Nathan CF. Secretory products of macrophages. J Clin Invest.1987;79:319-326.
28. Anghelina M, Krishnan P, Moldovan L, et al. Monocytes/macrophages cooperate with progenitor cells during neovascularization and tissue repair: conversion of cell columns into fibrovascular bundles. Am J Pathol. 2006;168:529-541.
29. Conejo-Garcia JR, Benencia F, Courreges MC, et al. Tumorinfiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of VEGF-A. Nat Med. 2004;10:950-958.
30. De Palma M, Venneri MA, Galli R, et al. TIE2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell. 2005;8:211-226.
31. Lin EY, Gouon-Evans V, Nguyen AV, et al. The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J Mammary Gland Biol Neoplasia. 2002;7: 147-162.
32. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71-78.
33. Kuroda T, Kitadai Y, Tanaka S, et al. Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment. Clin Cancer Res. 2005;11:7629-7636.
34. Hagemann T, Wilson J, Kulbe H, et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol. 2005;175:1197-1205.
35. Hagemann T, Robinson SC, Schulz M, et al. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis. 2004;25:1543-1549.
36. Schmeisser A, Marquetant R, Illmer T, et al. The expression of macrophage migration inhibitory factor 1alpha (MIF 1alpha) in human atherosclerotic plaques is induced by different proatherogenic stimuli and associated with plaque instability. Atherosclerosis.2005;178:83-94.
37. Sun B, Nishihira J, Yoshiki T, et al. Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the Rho-dependent pathway. Clin Cancer Res. 2005;11:1050-1058.
38. Wang FQ, So J, Reierstad S, et al. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer. 2005;114:19-31.
39. Lin CY, Lin CJ, Chen KH, et al. Macrophage activation increases the invasive properties of hepatoma cells by destabilization of the adherens junction. FEBS Lett. 2006;580:3042-3050.
40. Grimshaw MJ, Wilson JL, Balkwill FR. Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. Eur J Immunol. 2002;32:2393-2400.
41. Ehrenreich H, Anderson RW, Fox CH, et al. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med. 1990;172:1741-1748.
42. Grimshaw MJ. Endothelins in breast tumour cell invasion. Cancer Lett. 2005;222:129-138.
43. Junker N, Johansen JS, Andersen CB, et al. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer. 2005;48:223-231.
44. Pukrop T, Klemm F, Hagemann T, et al. Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines. Proc Natl Acad Sci U S A. 2006;103:5454-5459.
45. Ogawa E, Takenaka K, Yanagihara K, et al. Clinical significance of VEGF-C status in tumour cells and stromal macrophages in non-small cell lung cancer patients. Br J Cancer. 2004;91: 498-503.
46. Williams CS, Leek RD, Robson AM, et al. Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. J Pathol. 2003;200:195-206.
47. Jenny B, Harrison JA, Baetens D, et al. Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas. J Pathol. 2006;209:34-43.
48. Sica A, Saccani A, Bottazzi B, et al. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol. 2000;164:762-767.
49. Kambayashi T, Alexander HR, Fong M, et al. Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J Immunol. 1995;154:3383-3390.
50. Loercher AE, Nash MA, Kavanagh JJ, et al. Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol. 1999;163:6251-6260.
51. Valenti R, Huber V, Filipazzi P, et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res. 2006;66:9290-9298.
52. Li MO, Wan YY, Sanjabi S, et al. Transforming growth factorbeta regulation of immune responses. Annu Rev Immunol. 2006;24: 99-146.
53. Pardali K, Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta. 2007;1775:21-62.
54. Murata Y, Ohteki T, Koyasu S, et al. IFN-gamma and proinflammatory cytokine production by antigen-presenting cells is dictated by intracellular thiol redox status regulated by oxygen tension. Eur J Immunol. 2002;32:2866-2873.
55. Ertel W, Singh G, Morrison MH, et al. Chemically induced hypotension increases PGE2 release and depresses macrophage antigen presentation. Am J Physiol. 1993;264:R655-R660.
56. Biswas SK, Gangi L, Paul S, et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood. 2006;107:2112-2122.
57. Dinapoli MR, Calderon CL, Lopez DM. The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduce expression of the inducible nitric oxide synthase gene. J Exp Med. 1996;183:1323-1329.
58. Ibe S, Qin Z, Schuler T, et al. Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med. 2001;194:1549-1559.
59. Herbeuval JP, Lelievre E, Lambert C, et al. Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage-derived IL-6. J Immunol. 2004;172:4630-4636.
60. Shin HD, Park BL, Kim LH, et al. Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Hum Mol Genet. 2003;12:901-906.
61. Hagemann T, Wilson J, Burke F, et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol. 2006;176:5023-5032.
62. del Fresno C, Otero K, Gomez-Garcia L, et al. Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J Immunol.2005;174:3032-3040.
63. Watson GA, Lopez DM. Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses. J Immunol. 1995;155: 3124-3134.
64. Otsuji M, Kimura Y, Aoe T, et al. Oxidative stress by tumorderived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci U S A. 1996;93:13119-13124.
65. Kono K, Salazar-Onfray F, Petersson M, et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signaltransducing zeta molecules and inhibits tumor-specific T cell and natural killer cell-mediated cytotoxicity. Eur J Immunol. 1996;26: 1308-1313.
66. Ogden CA, Pound JD, Batth BK, et al. Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma. J Immunol. 2005;174:3015-3023.
67. Gordon IO, Freedman RS. Defective antitumor function of monocyte-derived macrophages from epithelial ovarian cancer patients. Clin Cancer Res. 2006;12:1515-1524.
68. Kryczek I, Zou L, Rodriguez P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med. 2006;203:871-881.
69. Kusmartsev S, Gabrilovich DI. STAT1 signaling regulates tumorassociated macrophage-mediated T cell deletion. J Immunol. 2005; 174:4880-4891.
70. Oosterling SJ, van der Bij GJ, Meijer GA, et al. Macrophages direct tumour histology and clinical outcome in a colon cancer model. J Pathol. 2005;207:147-155.
71. Sickert D, Aust DE, Langer S, et al. Characterization of macrophage subpopulations in colon cancer using tissue microarrays. Histopathology. 2005;46:515-521.
72. Leibovici J, Hoenig S. Lysis and growth stimulation of a murine melanoma determined by density of macrophage populations. Anticancer Res. 1985;5:545-551.
73. Cochran AJ, Huang RR, Lee J, et al. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol. 2006;6: 659-670.
74. Janeway CA Jr. The role of self-recognition in receptor repertoire development. Members of the Janeway Laboratory. Immunol Res.1999;19:107- 118.
75. Lackner C, Jukic Z, Tsybrovskyy O, et al. Prognostic relevance of tumour-associated macrophages and von Willebrand factor-positive microvessels in colorectal cancer. Virchows Arch. 2004;445: 160-167.
76. Tsung K, Dolan JP, Tsung YL, et al. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res. 2002;62:5069-5075.
77. Dileepan KN, Page JC, Li Y, et al. Direct activation of murine peritoneal macrophages for nitric oxide production and tumor cell killing by interferon-gamma. J Interferon Cytokine Res. 1995;15: 387-394.
78. Klimp AH, de Vries EG, Scherphof GL, et al. A potential role of macrophage activation in the treatment of cancer. Crit Rev Oncol Hematol. 2002;44:143-161.
79. Doe WF, Henson PM. Macrophage stimulation by bacterial lipopolysaccharides. I. Cytolytic effect on tumor target cells. J Exp Med. 1978;148:544-556.
80. Cameron DJ, Churchill WH. Cytotoxicity of human macrophages for tumor cells: enhancement by bacterial lipopolysaccharides (LPS). J Immunol. 1980;124:708-712.
81. Gardner CR, Wasserman AJ, Laskin DL. Liver macrophagemediated cytotoxicity toward mastocytoma cells involves phagocytosis of tumor targets. Hepatology. 1991;14:318-324.
82. Yang RB, Mark MR, Gray A, et al. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature. 1998;395: 284-288.
83. Sica A, Schioppa T, Mantovani A, et al. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42:717-727.
84. Nesbit M, Schaider H, Miller TH, et al. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol. 2001; 166:6483-6490.
85. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549-555.
86. Mikhak Z, Fleming CM, Medoff BD, et al. STAT1 in peripheral tissue differentially regulates homing of antigen-specific TH1 and TH2 cells. J Immunol. 2006;176:4959-4967.
87. Shoenfelt JL, Fenton MJ. TLR2-and TLR4-dependent activation of STAT1 serine phosphorylation in murine macrophages is protein kinase C-delta-independent. J Endotoxin Res. 2006;12:231-240.
88. Mantovani A, Allavena P, Sica A. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer. 2004;40:1660-1667.
89. Takaki H, Minoda Y, Koga K, et al. TGF-beta1 suppresses IFNgamma-induced NO production in macrophages by suppressing STAT1 activation and accelerating iNOS protein degradation. Genes Cells. 2006;11:871-882.
90. Utsugi T, Schroit AJ, Connor J, et al. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 1991;51:3062-3066.
91. Takano R, Nose M, Kanno H, et al. Recognition of N-glycosidic carbohydrates on esophageal carcinoma cells by macrophage cell line THP-1. Am J Pathol. 1990;137:393-401.
92. Ichii S, Imai Y, Irimura T. Initial steps in lymph node metastasis formation in an experimental system: possible involvement of recognition by macrophage C-type lectins. Cancer Immunol Immunother. 2000;49:1-9.
93. Putz EF, Mannel DN. Monocyte activation by tumour cells: a role for carbohydrate structures associated with CD2. Scand J Immunol.1995;41:77- 84.
94. Thomas P, Toth CA. Carcinoembryonic antigen binding to Kupffer cells is via a peptide located at the junction of the N-terminal and first loop domains. Biochem Biophys Res Commun.1990;170:391-396.
95. Zeng G, Aldridge ME, Tian X, et al. Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system. J Immunol.2006;177:3582-3589.
96. Shaw GM, Levy PC, Lobuglio AF. Human monocyte cytotoxicity to tumor cells. I. Antibody-dependent cytotoxicity. J Immunol.1978;121:573-578.
97. Kawase I, Komuta K, Ogura T, et al. Murine tumor cell lysis by antibody-dependent macrophage-mediated cytotoxicity using syngeneic monoclonal antibodies. Cancer Res. 1985;45: 1663-1668.
98. Zembala M, Siedlar M, Marcinkiewicz J, et al. Human monocytes are stimulated for nitric oxide release in vitro by some tumor cells but not by cytokines and lipopolysaccharide. Eur J Immunol. 1994; 24:435-439.
99. Mytar B, Siedlar M, Woloszyn M, et al. Cross-talk between human monocytes and cancer cells during reactive oxygen intermediates generation: the essential role of hyaluronan. Int J Cancer. 2001; 94:727-732.
100. Houghton AM, Grisolano JL, Baumann ML, et al. Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res. 2006;66:6149-6155.
101. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79:315-328.
102. Gorrin-Rivas MJ, Arii S, Mori A, et al. Implications of human macrophage metalloelastase and vascular endothelial growth factor gene expression in angiogenesis of hepatocellular carcinoma. Ann Surg. 2000;231:67-73.
103. Yang W, Arii S, Gorrin-Rivas MJ, et al. Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance. Cancer. 2001;91:1277-1283.
104. Gorrin-Rivas MJ, Arii S, Furutani M, et al. Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis. Clin Cancer Res.2000;6:1647-1654.
105. Stanley ER, Berg KL, Einstein DB, et al. The biology and action of colony stimulating factor-1. Stem Cells. 1994;12(suppl 1):15-24; discussion 25.
106. Lehtonen A, Ahlfors H, Veckman V, et al. Gene expression profiling during differentiation of human monocytes to macrophages or dendritic cells. J Leukoc Biol. 2007;82:710-720.
107. Zhou LJ, Tedder TF. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA. 1996;93:2588-2592.
108. Mohamadzadeh M, Berard F, Essert G, et al. Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med. 2001;194:1013-1020.
109. Iwamoto S, Iwai S, Tsujiyama K, et al. TNF-alpha drives human CD14+ monocytes to differentiate into CD70+ dendritic cells evoking TH1 and TH17 responses. J Immunol. 2007;179: 1449-1457.
110. Buisson S, Triebel F. LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors. Immunology.2005;114:369-374.
111. Chomarat P, Banchereau J, Davoust J, et al. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol. 2000;1:510-514.
112. Allavena P, Piemonti L, Longoni D, et al. IL-10 prevents the generation of dendritic cells from CD14+ blood monocytes, promotes the differentiation to mature macrophages and stimulates endocytosis of FITC-dextran. Adv Exp Med Biol. 1997;417: 323-327.
113. Delneste Y, Charbonnier P, Herbault N, et al. Interferon-gamma switches monocyte differentiation from dendritic cells to macrophages. Blood. 2003;101:143-150.
114. Furihata M, Ohtsuki Y, Ido E, et al. HLA-DR antigen-and S-100 protein-positive dendritic cells in esophageal squamous cell carcinoma-their distribution in relation to prognosis. Virchows Arch B Cell Pathol Incl Mol Pathol. 1992;61:409-414.
115. Inoue K, Furihata M, Ohtsuki Y, et al. Distribution of S-100 protein-positive dendritic cells and expression of HLA-DR antigen in transitional cell carcinoma of the urinary bladder in relation to tumour progression and prognosis. Virchows Arch A Pathol Anat Histopathol. 1993;422:351-355.
116. Ambe K, Mori M, Enjoji M. S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer. 1989;63:496-503.
117. Byrne SN, Halliday GM. Phagocytosis by dendritic cells rather than MHC II high macrophages is associated with skin tumour regression. Int J Cancer. 2003;106:736-744.
118. Wei N, Tahan SR. S100+ cell response to squamous cell carcinoma of the lip: inverse correlation with metastasis. J Cutan Pathol.1998;25:463-468.
119. Matsuda H, Mori M, Tsujitani S, et al. Immunohistochemical evaluation of squamous cell carcinoma antigen and S-100 proteinpositive cells in human malignant esophageal tissues. Cancer.1990;65:2261-2265.
120. Vakkila J, Lotze MT, Riga C, et al. A basis for distinguishing cultured dendritic cells and macrophages in cytospins and fixed sections. Pediatr Dev Pathol. 2005;8:43-51.
121. Albert ML, Pearce SF, Francisco LM, et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med.1998;188:1359-1368.
122. Buttiglieri S, Galetto A, Forno S, et al. Influence of drug-induced apoptotic death on processing and presentation of tumor antigens by dendritic cells. Int J Cancer. 2003;106:516-520.
123. Chen Z, Moyana T, Saxena A, et al. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer. 2001;93:539-548.
124. Kurosaka K, Watanabe N, Kobayashi Y. Potentiation by human serum of anti-inflammatory cytokine production by human macrophages in response to apoptotic cells. J Leukoc Biol. 2002; 71:950-956.
125. Goldszmid RS, Idoyaga J, Bravo AI, et al. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J Immunol. 2003; 171:5940-5947.
126. Fadok VA, Bratton DL, Guthrie L, et al. Differential effects of apoptotic versus lysed cells on macrophage production of cytokines: role of proteases. J Immunol. 2001;166:6847-6854.
127. Calderon C, Huang ZH, Gage DA, et al. Isolation of a nitric oxide inhibitor from mammary tumor cells and its characterization as phosphatidyl serine. J Exp Med. 1994;180:945-958.
128. Yang R, Xu D, Zhang A, et al. Immature dendritic cells kill ovarian carcinoma cells by a FAS/FASL pathway, enabling them to sensitize tumor-specific CTLs. Int J Cancer. 2001;94:407-413.
129. Yagita H, Takeda K, Hayakawa Y, et al. TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 2004;95:777-783.
130. Fanger NA, Maliszewski CR, Schooley K, et al. Human dendritic cells mediate cellular apoptosis via tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL). J Exp Med. 1999;190: 1155-1164.
131. Lu G, Janjic BM, Janjic J, et al. Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol. 2002;168:1831-1839.
132. Cappello P, Novelli F, Forni G, et al. Death receptor ligands in tumors. J Immunother. 2002;25:1-15.
133. Liu S, Yu Y, Zhang M, et al. The involvement of TNFalpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. J Immunol. 2001;166:5407-5415.
134. Taieb J, Chaput N, Menard C, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med. 2006;12:214-219.
135. Shi J, Ikeda K, Fujii N, et al. Activated human umbilical cord blood dendritic cells kill tumor cells without damaging normal hematological progenitor cells. Cancer Sci. 2005;96:127-133.
136. Rowinsky EK. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosisinducing ligand receptor activating agents. J Clin Oncol. 2005;23: 9394-9407.
137. Enzler T, Gillessen S, Manis JP, et al. Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J Exp Med. 2003; 197:1213-1219.